AG-221 (Enasidenib), IHD2 Inhibitor


Catalog No. size PriceQuantity
M60296-2S 2 mg solid $129
M60296-10S 10 mg solid $510

Description

Product Information
Molecular Weight: 473.38
Formula: C19H17F6N7O
Purity: ≥98%
CAS#: 1446502-11-9
Solubility: DMSO up to 50 mM
Chemical Name: 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

AG-221 (Enasidenib) is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 ~16 nM. It can reduce intracellular and extracellular levels of 2-HG in TF-1/IDH2 (R140Q) mutant cells in a dose-dependent manner. It can reduce IDH2 (R140Q)-induced GM-CSF-independent growth, reduce histone hypermethylation associated with elevated levels of 2-HG. In vivo treatment with AG-221 in U87MG IDH2 (R140Q) tumor xenograft model lead to a reduction in tumor 2-HG concentration. A dose dependent decrease in leukemia and evidence of normal differentiation was seen in AG-221 treated NOD/SCID mice engrafted with AMM7577-P2 cells. Now the drug is in clinical trials for IDH2 mutant-positive AML.

How to Use:

In vitro:
 AG-221 was used at 1 µM in vitro and cellular assays.
In vivo:
 AG-221 was dosed orally to mice bearing IDH2 mutant tumors at 5-50 mg/Kg once per day.


Reference:

  • 1. http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-publications
  • 2. Chong-Hui Gu, et al. Crystalline forms of therapeutically active compounds and use thereof. (2015) PCT WO 2015018060

Products are for research use only. Not for human use. 

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed